Results at 48 weeks in the TENAYA and LUCERNE phase 3 trials showed positive outcomes of faricimab for neovascular age-related macular degeneration.
Dosing intervals were between 12 and 16 weeks in 80% of the patients.
“Faricimab is the first bispecific antibody designed for intraocular use. It targets and neutralizes both Ang-2 and VEGF-A in order to stabilize vessels as well as reduce vascular hyperpermeability, inflammation and neovascularization,” Frank G. Holz, MD, PhD, said at the virtual Euretina congress.
The two studies enrolled a total of 1,329 patients across 271 sites